- Home
- MTEX vs HOOK Comparison
MTEX vs HOOK Comparison
Compare MTEX & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- HOOK
- Stock Information
- Founded
- MTEX 1993
- HOOK 2011
- Country
- MTEX United States
- HOOK United States
- Employees
- MTEX N/A
- HOOK N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- HOOK Health Care
- Exchange
- MTEX Nasdaq
- HOOK Nasdaq
- Market Cap
- MTEX 19.9M
- HOOK 9.3M
- IPO Year
- MTEX 1999
- HOOK 2019
- Fundamental
- Price
- MTEX $10.00
- HOOK $1.47
- Analyst Decision
- MTEX
- HOOK Buy
- Analyst Count
- MTEX 0
- HOOK 4
- Target Price
- MTEX N/A
- HOOK $10.67
- AVG Volume (30 Days)
- MTEX 1.7K
- HOOK 134.3K
- Earning Date
- MTEX 05-20-2025
- HOOK 05-20-2025
- Dividend Yield
- MTEX N/A
- HOOK N/A
- EPS Growth
- MTEX N/A
- HOOK N/A
- EPS
- MTEX 1.32
- HOOK N/A
- Revenue
- MTEX $117,866,000.00
- HOOK $43,946,000.00
- Revenue This Year
- MTEX N/A
- HOOK N/A
- Revenue Next Year
- MTEX N/A
- HOOK N/A
- P/E Ratio
- MTEX $7.58
- HOOK N/A
- Revenue Growth
- MTEX N/A
- HOOK 118.32
- 52 Week Low
- MTEX $6.75
- HOOK $0.72
- 52 Week High
- MTEX $16.49
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- MTEX 49.29
- HOOK 67.61
- Support Level
- MTEX $9.70
- HOOK $1.14
- Resistance Level
- MTEX $11.90
- HOOK $1.67
- Average True Range (ATR)
- MTEX 0.26
- HOOK 0.16
- MACD
- MTEX -0.03
- HOOK 0.10
- Stochastic Oscillator
- MTEX 24.00
- HOOK 78.69
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.